Karen E Kunzel, MD
Obstetrics/Gynecology · Los Gatos
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- 12
- 1 carrier
- Offices
- 4
On the public record
- California licence: Probation - Licensee Placed on Probation
- 1 Medical Board action on record
Offices
4 locations · University Healthcare Alliance · 334 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kunzel’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G69747 · Current
Licensed to practise in California · since 1990 · expires 2028-03-31 · University of Southern California Keck School of Medicine. Board flags: Probation - Licensee Placed on Probation, Limitations on Practice.
Public record actions
| 2024-07-31 | Board disciplineDiscipline | Thirty-five months' probation with various terms and conditions. restrictions: prohibited from supervising physician assistants and advanced practice nurses. · 8002020068419 |
Respondent made no admissions but was charged with gross negligence, repeated negligent acts, incompetence, and unprofessional conduct in the care and treatment of one patient. Acceptance of this stipulated settlement is not an admission of guilt. Effective 07/31/2024, revoked, stayed, placed on thirty-five months' probation until anticipated end date of 06/29/2027. Terms and conditions include, but are not limited to, completing an education course; completing a clinical competence assessment program; submitting proof of notification of Decision and Accusation to required parties; prohibited from supervising physician assistants and advanced practice nurses; reimbursing the Board its costs of investigation and enforcement in the amount of $35,863.80; submitting quarterly declarations of compliance with all conditions of probation; complying with the Board's probation unit; prohibited from engaging in the practice of medicine in Respondent's or patient's place of residence, unless the patient resides in a skilled nursing facility or other similar licensed facility; and paying costs associated with probation monitoring.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$26,990
Medicare paid this office $26,990 for 192 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 70 | $5,762 | $71 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 118 | $5,643 | $48 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 79 | $4,528 | $57 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 19 | $2,403 | $114 |
| New patient visit (30+ min) | 13 | $1,383 | $106 |
See all 6 services
| Short return visit (20+ min) | 70 | $5,762 | $71 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 118 | $5,643 | $48 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 79 | $4,528 | $57 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 19 | $2,403 | $114 |
| New patient visit (30+ min) | 13 | $1,383 | $106 |
| Short return visit | 22 | $1,287 | $56 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
192 Original Medicare patients in 2024. Average age 73 · Women 100% · Health risk score 0.72. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 62% · Depression 16% · Coronary heart disease 15% · Diabetes 14% · Cancer 14% · Chronic kidney disease 11% · Atrial fibrillation 10%.
The office billed $103,259, Medicare allowed $33,641 and paid $26,990; for 403 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 192 | 403 | 73 | 0.72 | $103,259 | $26,990 |
| 2023 | 192 | 418 | 74 | 0.74 | $97,360 | $27,302 |
| 2022 | 164 | 407 | 73 | 0.78 | $90,394 | $25,717 |
| 2021 | 141 | 328 | 73 | 0.67 | $82,768 | $20,101 |
| 2020 | 121 | 211 | 73 | 0.75 | $58,452 | $13,221 |
| 2019 | 136 | 213 | 72 | 0.74 | $53,260 | $11,858 |
| 2018 | 196 | 387 | 73 | 0.77 | $92,396 | $19,871 |
| 2017 | 191 | 409 | 72 | 0.77 | $90,238 | $22,073 |
| 2016 | 188 | 412 | 72 | 0.79 | $104,390 | $22,203 |
| 2015 | 214 | 561 | 73 | 0.75 | $84,746 | $29,388 |
| 2014 | 190 | 578 | 71 | 0.67 | $67,158 | $33,210 |
| 2013 | 153 | 352 | 72 | 0.68 | $41,387 | $21,048 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Short return visit (20+ min) | 80 | $7,012 | $78 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 112 | $5,352 | $48 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 80 | $4,470 | $56 |
| Return visit (30+ min) | 22 | $2,354 | $107 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,537 | $110 |
| Influenza vaccine split virus, preservative free | 14 | $1,007 | $72 |
| Administration of influenza virus vaccine | 14 | $517 | $37 |
| Automated urinalysis test | 16 | $35 | $2 |
2022: 9 services
| Short return visit (20+ min) | 54 | $5,114 | $77 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 95 | $4,537 | $48 |
| Return visit (30+ min) | 28 | $3,465 | $105 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 62 | $3,416 | $55 |
| New patient visit (30+ min) | 15 | $1,454 | $97 |
| Influenza vaccine split virus, preservative free | 13 | $884 | $68 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 35 | $623 | $18 |
| Administration of influenza virus vaccine | 14 | $523 | $37 |
| Automated urinalysis test | 17 | $42 | $2 |
2021: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 98 | $4,823 | $49 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 70 | $3,961 | $57 |
| Short return visit (20+ min) | 35 | $3,655 | $87 |
| Return visit (30+ min) | 11 | $1,344 | $122 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 28 | $505 | $18 |
2020: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 72 | $3,536 | $49 |
| Short return visit (20+ min) | 42 | $3,281 | $64 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,422 | $129 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $611 | $56 |
2019: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 92 | $4,366 | $47 |
| Short return visit (20+ min) | 32 | $2,210 | $61 |
| Return visit (30+ min) | 11 | $958 | $80 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $824 | $55 |
2018: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 121 | $5,515 | $46 |
| Short return visit (20+ min) | 56 | $3,997 | $57 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 41 | $2,267 | $55 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 16 | $1,650 | $103 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 77 | $1,482 | $19 |
2017: 8 services
| Short return visit (20+ min) | 54 | $5,300 | $64 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 106 | $4,869 | $46 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 46 | $2,556 | $56 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 18 | $2,348 | $124 |
| New patient visit (45+ min) | 14 | $2,009 | $143 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 67 | $1,432 | $21 |
| New patient visit (30+ min) | 12 | $1,014 | $84 |
| Automated urinalysis test | 17 | $60 | $3 |
2016: 6 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 107 | $4,849 | $45 |
| Short return visit (20+ min) | 54 | $3,860 | $58 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 46 | $2,547 | $55 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 17 | $1,731 | $96 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 80 | $1,699 | $21 |
| New patient visit (45+ min) | 13 | $1,586 | $122 |
2015: 12 services
| Short return visit (20+ min) | 92 | $7,026 | $60 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 96 | $4,354 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 55 | $3,009 | $55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 19 | $2,634 | $139 |
| Return visit (30+ min) | 23 | $2,077 | $87 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 92 | $1,952 | $21 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,643 | $110 |
| Dxa bone density measurement of hip, pelvis, spine | 25 | $1,257 | $50 |
| New patient visit (30+ min) | 13 | $955 | $73 |
| New patient visit (15+ min) | 13 | $734 | $56 |
| Manual urinalysis test with examination using microscope, non-automated | 32 | $156 | $4 |
| Stool analysis for blood to screen for colon tumors | 14 | $61 | $4 |
2014: 10 services
| Short return visit (20+ min) | 102 | $8,248 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 107 | $4,806 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 62 | $3,342 | $54 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 19 | $2,472 | $124 |
| Dxa bone density measurement of hip, pelvis, spine | 35 | $2,190 | $63 |
| New patient visit (45+ min) | 15 | $1,889 | $126 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 87 | $1,850 | $21 |
| New patient visit (30+ min) | 21 | $1,743 | $83 |
| Return visit (30+ min) | 11 | $1,148 | $77 |
| Manual urinalysis test with examination using microscope, non-automated | 19 | $115 | $4 |
2013: 7 services
| Short return visit (20+ min) | 79 | $5,722 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 78 | $3,505 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 36 | $1,947 | $54 |
| Dxa bone density measurement of hip, pelvis, spine | 27 | $1,725 | $64 |
| New patient visit (30+ min) | 16 | $1,552 | $97 |
| Return visit (30+ min) | 12 | $1,094 | $84 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 33 | $690 | $21 |
Drugs they prescribed that Part D paid
$38,836
Pharmacies billed $38,836 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
314 generic and 81 brand-name prescriptions · $38,836 in drug cost · 26 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 68 | $6,101 | $90 |
| Yuvafem | 18 | $4,192 | $233 |
| Estradiol (Twice Weekly) | 26 | $1,301 | $50 |
| Progesterone | 35 | $1,189 | $34 |
| Clobetasol Propionate | 14 | $464 | $33 |
See all 10 drugs
| Estradiol | 68 | $6,101 | $90 |
| Yuvafem | 18 | $4,192 | $233 |
| Estradiol (Twice Weekly) | 26 | $1,301 | $50 |
| Progesterone | 35 | $1,189 | $34 |
| Clobetasol Propionate | 14 | $464 | $33 |
| Valacyclovir | 27 | $423 | $16 |
| Nitrofurantoin Mono-Macro | 15 | $168 | $11 |
| Acyclovir | 11 | $160 | $15 |
| Triamcinolone Acetonide | 18 | $93 | $5 |
| Sertraline | 11 | $82 | $7 |
Year by year
| 2024 | 395 | 123 | None | 21% | $38,836 |
| 2023 | 304 | 102 | 0% (0) | None | $33,689 |
| 2022 | 245 | 92 | 0% (0) | 22% | $28,684 |
| 2021 | 193 | 61 | 0% (0) | 31% | $24,975 |
| 2020 | 204 | 53 | 0% (0) | 28% | $18,883 |
| 2019 | 189 | 71 | 0% (0) | 26% | $18,073 |
| 2018 | 213 | 79 | None | 24% | $27,636 |
| 2017 | 259 | 85 | 0% (0) | 21% | $36,692 |
| 2016 | 225 | 78 | 0% (0) | 27% | $20,632 |
| 2015 | 253 | 70 | 0% (0) | 30% | $22,445 |
| 2014 | 274 | 58 | 0% (0) | 42% | $30,393 |
| 2013 | 216 | 53 | 0% (0) | 40% | $18,109 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Estradiol | 58 | $5,854 | $101 |
| Yuvafem | 19 | $3,200 | $168 |
| Estradiol (Twice Weekly) | 15 | $852 | $57 |
| Clobetasol Propionate | 11 | $807 | $73 |
| Valacyclovir | 15 | $627 | $42 |
| Progesterone | 13 | $508 | $39 |
| Nitrofurantoin Mono-Macro | 14 | $184 | $13 |
| Sertraline | 16 | $151 | $9 |
| Triamcinolone Acetonide | 16 | $81 | $5 |
2022: 7 drugs
| Estradiol | 32 | $2,911 | $91 |
| Estradiol (Once Weekly) | 13 | $2,024 | $156 |
| Valacyclovir | 23 | $728 | $32 |
| Progesterone | 14 | $563 | $40 |
| Nitrofurantoin Mono-Macro | 15 | $266 | $18 |
| Triamcinolone Acetonide | 20 | $139 | $7 |
| Sertraline | 13 | $88 | $7 |
2021: 6 drugs
| Estradiol (Once Weekly) | 16 | $1,727 | $108 |
| Estradiol | 18 | $1,280 | $71 |
| Valacyclovir | 19 | $1,197 | $63 |
| Progesterone | 11 | $623 | $57 |
| Triamcinolone Acetonide | 15 | $92 | $6 |
| Paroxetine | 14 | $84 | $6 |
2020: 6 drugs
| Estradiol (Once Weekly) | 27 | $3,523 | $130 |
| Premarin | 11 | $2,393 | $218 |
| Estradiol | 15 | $1,501 | $100 |
| Progesterone | 22 | $609 | $28 |
| Valacyclovir | 18 | $545 | $30 |
| Triamcinolone Acetonide | 12 | $63 | $5 |
2019: 4 drugs
| Estradiol | 43 | $4,486 | $104 |
| Yuvafem | 12 | $2,796 | $233 |
| Progesterone | 12 | $755 | $63 |
| Valacyclovir | 12 | $362 | $30 |
2018: 4 drugs
| Yuvafem | 20 | $5,708 | $285 |
| Estradiol | 41 | $5,684 | $139 |
| Ibandronate | 11 | $2,057 | $187 |
| Valacyclovir | 21 | $682 | $32 |
2017: 8 drugs
| Yuvafem | 17 | $7,408 | $436 |
| Estrace | 14 | $6,299 | $450 |
| Estradiol | 38 | $3,890 | $102 |
| Ibandronate | 13 | $2,366 | $182 |
| Valacyclovir | 31 | $1,457 | $47 |
| Zolpidem | 16 | $283 | $18 |
| Fluoxetine | 12 | $128 | $11 |
| Alendronate | 14 | $86 | $6 |
2016: 10 drugs
| Vagifem | 13 | $5,218 | $401 |
| Premarin | 12 | $3,495 | $291 |
| Estradiol | 26 | $2,011 | $77 |
| Ibandronate | 11 | $1,915 | $174 |
| Progesterone | 11 | $667 | $61 |
| Valacyclovir | 23 | $655 | $28 |
| Levothyroxine | 15 | $424 | $28 |
| Nitrofurantoin Mono-Macro | 14 | $414 | $30 |
| Zolpidem | 14 | $354 | $25 |
| Alendronate | 11 | $163 | $15 |
2015: 8 drugs
| Vagifem | 23 | $5,750 | $250 |
| Ibandronate | 15 | $2,532 | $169 |
| Estradiol | 28 | $1,582 | $56 |
| Estrace | 13 | $1,540 | $118 |
| Progesterone | 12 | $982 | $82 |
| Valacyclovir | 16 | $920 | $57 |
| Calcitonin-Salmon | 12 | $596 | $50 |
| Levothyroxine | 21 | $591 | $28 |
2014: 9 drugs
| Vagifem | 30 | $7,534 | $251 |
| Vivelle-Dot | 22 | $4,501 | $205 |
| Progesterone | 18 | $1,873 | $104 |
| Estrace | 13 | $1,282 | $99 |
| Calcitonin-Salmon | 14 | $1,090 | $78 |
| Valacyclovir | 17 | $996 | $59 |
| Estradiol | 21 | $615 | $29 |
| Levothyroxine | 18 | $367 | $20 |
| Amitriptyline | 11 | $72 | $7 |
2013: 5 drugs
| Vagifem | 26 | $4,139 | $159 |
| Actonel | 13 | $1,983 | $153 |
| Calcitonin-Salmon | 16 | $1,168 | $73 |
| Zolpidem | 15 | $129 | $9 |
| Estradiol | 16 | $82 | $5 |
Money from drug and device companies
$154 in 2025
| 2025 | 2 | 2 | None | $154 |
| 2024 | 1 | 1 | None | $25 |
| 2023 | 1 | 4 | None | $30 |
| 2022 | 1 | 2 | None | $111 |
| 2021 | 2 | 2 | None | $39 |
| 2020 | 3 | 8 | None | $237 |
| 2019 | 5 | 16 | $3,200 | $4,160 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Nurtec Odt | $125 | 1 payment
|
| Hologic Sales and Service | Aptima | $29 | 1 payment
|
See all 2 published payments
| Pfizer | Meals · 2025-08-28 | Nurtec Odt | $125 |
| Hologic Sales and Service | Meals · 2025-05-20 | Aptima | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $25
| Hologic Sales and Service | Aptima | $25 | 1 payment
|
2023: $30
| Mayne Pharma Commercial | None | $30 | 4 payments
|
2022: $111
| Medtronic | Venaseal | $111 | 2 payments
|
2021: $39
| AbbVie | Lo Loestrin Fe | $22 | 1 payment
|
| Myovant Sciences | Myfembree | $18 | 1 payment
|
2020: $237
| AbbVie | Liletta | $114 | 6 payments
|
| Sage Therapeutics | Zulresso | $111 | 1 payment
|
| TherapeuticsMD | Annovera | $11 | 1 payment
|
2019: $4,160
| Gen-Probe Sales & Service | Aptima M Genitalium | $3,813 | 3 payments
|
| AbbVie | Orilissa | $270 | 8 payments
|
| Allergan | Lo Loestrin Fe | $42 | 3 payments
|
| Edwards Lifesciences | Clearsight System | $23 | 1 payment
|
| TherapeuticsMD | Imvexxy | $13 | 1 payment
|
Professional record
- NPI
- 1184689911
- Licence
- CA G69747California G69747: Current · expires 2028-03-31
- Trained
- University of Southern California Keck School of Medicine, 1989
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 15151 National Ave, Los Gatos, CA, 95032
- NPI first listed
- 2006-04-17
- NPI last updated
- 2007-07-09
This is when the NPI record was last certified, not a medical board exam.